Ceftaroline Fosamil 7-Positionis Pars Catena CAS 75028-24-9 Puritas: ≥99.0% (HPLC) Imago Featured

Ceftaroline Fosamil 7-Positionis Pars Catenae CAS 75028-24-9 Puritas: ≥99.0% (HPLC)

Description:

(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl) -2-(ethoxyimino)acidi acetici;Ceftaroline Fosamil 7-Position Side Chain

CAS: 75028-24-9

Puritas: ≥99.0% (HPLC)

Aspectus: Alba ad lux Yellow Crystallina pulveris

Intermedia Ceftaroline Fosamil (TAK-599), a Cephalosporin derivativa

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple cum High puritate et stabulo Quality
Nomen chemicum: (Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl) -2-(ethoxyimino) acidum aceticum
CAS: 75028-24-9

Chemical Properties:

Nomen chemicum	(Z) -2-(5-Amino-1,2,4-thiadiazol-3-yl) -2-(ethoxyimino) aceticum
Synonyma	Ceftaroline Fosamil 7-Position Side Chain;ATDE
CAS Number	75028-24-9
CATTUS Number	RF-PI559
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C6H8N4O3S
M. Pondus	216.22
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad lux Yellow Crystallina pulveris
Puritas / Analysis Methodus	≥99.0% (HPLC)
Humor (KF)	≤0.50%
una immunditia	≤0.50%
Totalis immunditias	≤1.0%
Test Standard	Enterprise Standard
Consuetudinem	Intermedia Ceftaroline Fosamil (TAK-599), a Cephalosporin derivativa

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl) -2-(ethoxyimino) acidum aceticum (CAS: 75028-24-9) medium magni momenti est ad praeparationem Ceftarolini Fosamil. (TAK-599).Ceftaroline fosamil est cephalosporinum cum activo contra pathogens gram-positivum, inter methicillinum-resistentem Staphylococcus aureus (MRSA).Ceftaroline Fosamil prodrug Ceftaroline eft.Augetur ab Forest Laboratorium, sub licentia de Takeda.Accepit approbationem a Cibus US et Drug Administration (FDA) pro curatione communitatis bacterial pneumonia acquisita et infectiones cutis bacterial acuta die 29 Octobris 2010.